Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer with PD-L1-positive: a cost-effectiveness analysis

Health Economics Review · Published 2026-07-23 · DOI 10.1186/s13561-026-00824-x

Free full text

Authors (10)

Binliang Liu, Tao Wu, Fang Xu, Dongmei Sun, Yu Tang, Can Tian, Liping Liu, Zheyu Hu, Quchang Ouyang, Ning Xie

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Liu, B., Wu, T., Xu, F., et al. (2026). Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer with PD-L1-positive: a cost-effectiveness analysis. Health Economics Review. https://doi.org/10.1186/s13561-026-00824-x

Related articles